Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Shares Soar 53% on Collaboration News

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Shares Soar 53% on Collaboration News


Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are 53% higher during afternoon trading Wednesday, putting PIRS shares up more than 110% for 2017 as volume and full liquidity has been the story on the back of the news for the company.  A look at the price action below shows the current news has firmly taken hold. Pieris was the number one mover Wednesday in US Markets. Let’s have a look at the news below.

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced Wednesday, a strategic collaboration in respiratory diseases with AstraZeneca to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform, including its lead preclinical drug candidate, PRS-060.

Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung.

Under the collaboration, Pieris will be responsible for advancing its preclinical lead candidate, PRS-060, into Phase 1 clinical trials in 2017. PRS-060 is an Anticalin against interleukin-4 receptor alpha (IL-4Ra) with potential in asthma. AstraZeneca will fund all clinical development and subsequent commercialization programs and Pieris has the option of co-development and co-commercialization in the US from Phase 2a onwards. In addition, the parties will collaborate to progress four additional novel Anticalins against undisclosed targets for respiratory diseases with Pieris having the option to co-develop and co-commercialize in the US two of these programs.

Subscribe below and we’ll keep you on top of what’s happening before $PIRS stock makes its next move.

$PIRS 10-Day Chart Below:

Mene Pangalos, Executive Vice President, Innovative Medicines and Early Development Biotech Unit and Business Development, said: “At AstraZeneca, discovering and developing innovative new medicines to treat respiratory diseases is a key strategic priority. Our alliance with Pieris adds an important new modality to our respiratory portfolio and builds on our scientific expertise in inhaled formulation technologies. Pieris shares our passion for ground-breaking science and we look forward to working together to develop new, life-changing treatment options for patients.”

Stephen Yoder, President and Chief Executive Officer of Pieris, said: “Our partnership with AstraZeneca accelerates the transformation of Pieris into a fully-integrated drug development and commercial organization, comprising two main pillars in immunology: respiratory diseases and immuno-oncology, each of which is now anchored by a major alliance. We recognize AstraZeneca’s unparalleled expertise in the development of inhaled drugs, which will maximize the potential of PRS-060 and other inhaled Anticalin molecules to become valuable assets for both companies.”

AstraZeneca will make an upfront and near term milestone payments to Pieris in the amount of $57.5 million — $45 million USD of upfront payments and $12.5 million USD for the initiation of the PRS-060 Phase 1 trial. Pieris has the potential to receive development-dependent milestones and eventual commercial payments for all products not exceeding $2.1 billion as well as tiered royalties on the sales of any potential products commercialized by AstraZeneca. For programs co-developed by Pieris, the Company stands to receive increased royalties or a gross margin share on worldwide sales equal, dependent on the level of investment to which Pieris commits.

Louis Matis, M.D., Senior Vice President and Chief Development Officer of Pieris, said: “AstraZeneca, a leading innovator in respiratory diseases with considerable expertise in the development of inhaled products, is the ideal partner to exploit the potential of our platform in respiratory diseases. Based on the limitations of many types of biologic molecules, direct delivery to the lungs via inhalation has been challenging to date for other classes of therapeutic proteins. Anticalin proteins have unique properties, not least of which is their size and stability, and show considerable promise for this route of delivery.”

Pieris Pharmaceuticals, Inc. (NasdaqMKTS:PIRS) has justly rewarded shareholders who sat through a tough 2016 with not much more than sideways moves. 2017 has been another story for them with the AstraZeneca deal as they trade higher today by 50% plus. Getting this boost is excellent for the industry in general as the deal pipeline seems reinvigorated. For more news on PIRS and other fast-moving penny stocks, please subscribe to OracleDispatch.com below.

Sign Up for our 100% FREE Oracle Dispatch Newsletter